Mohsen Damavandi, PhD
The Cardiovascular Health across the Lifespan Program (CHAL) includes fundamental , clinical and evaluative research platforms. Basic research in this program focuses on the study of biomarkers, histopathology, genetics, translational genomics and genetic epidemiology. Biomedical and clinical research is conducted in the domains of biodesign, health technology, regenerative medicine and information technology, with observational cardiovascular studies and clinical trials completed or underway. CHAL investigators with expertise in epidemiology conduct population health, outcomes and health services research.
The CHAL Program is primarily located at the Glen site of the Research Institute of the McGill University Health Centre (RI‑MUHC), with several of its members at the Montreal General Hospital of the MUHC site. CHAL investigators perform research at the Centre for Translational Biology, the Centre for Innovative Medicine and the Centre for Health Outcomes Research at the RI‑MUHC.
The Cardiovascular Health across the Lifespan Program (CHAL) Program is centered around three main research themes:
Review our research highlights and publications in the 2022 RI-MUHC Annual Report.
Researchers in the CHAL program are involved in a multitude of research initiatives, including:
The Research Institute of the McGill University Health Centre (RI-MUHC) is a world-renowned biomedical and healthcare research centre. The Institute, which is affiliated with the Faculty of Medicine of McGill University, is the research arm of the McGill University Health Centre (MUHC) – an academic health centre located in Montreal, Canada, that has a mandate to focus on complex care within its community. The RI-MUHC supports over 460 researchers and close to 1,200 research trainees devoted to a broad spectrum of fundamental, clinical and health outcomes research at the Glen and the Montreal General Hospital sites of the MUHC.